- Home
- LPAA vs MNPR Comparison
LPAA vs MNPR Comparison
Compare LPAA & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPAA
- MNPR
- Stock Information
- Founded
- LPAA 2024
- MNPR 2014
- Country
- LPAA United States
- MNPR United States
- Employees
- LPAA N/A
- MNPR N/A
- Industry
- LPAA
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- LPAA
- MNPR Health Care
- Exchange
- LPAA Nasdaq
- MNPR Nasdaq
- Market Cap
- LPAA 290.4M
- MNPR 244.1M
- IPO Year
- LPAA 2024
- MNPR 2019
- Fundamental
- Price
- LPAA $10.20
- MNPR $33.43
- Analyst Decision
- LPAA
- MNPR Strong Buy
- Analyst Count
- LPAA 0
- MNPR 5
- Target Price
- LPAA N/A
- MNPR $49.60
- AVG Volume (30 Days)
- LPAA 46.2K
- MNPR 30.2K
- Earning Date
- LPAA 01-01-0001
- MNPR 05-08-2025
- Dividend Yield
- LPAA N/A
- MNPR N/A
- EPS Growth
- LPAA N/A
- MNPR N/A
- EPS
- LPAA N/A
- MNPR N/A
- Revenue
- LPAA N/A
- MNPR N/A
- Revenue This Year
- LPAA N/A
- MNPR N/A
- Revenue Next Year
- LPAA N/A
- MNPR N/A
- P/E Ratio
- LPAA $47.69
- MNPR N/A
- Revenue Growth
- LPAA N/A
- MNPR N/A
- 52 Week Low
- LPAA $9.66
- MNPR $1.72
- 52 Week High
- LPAA $10.22
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- LPAA N/A
- MNPR 45.29
- Support Level
- LPAA N/A
- MNPR $36.80
- Resistance Level
- LPAA N/A
- MNPR $43.00
- Average True Range (ATR)
- LPAA 0.00
- MNPR 5.63
- MACD
- LPAA 0.00
- MNPR 0.16
- Stochastic Oscillator
- LPAA 0.00
- MNPR 21.49
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.